Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

BMC Infectious Diseases
Juan PasquauRIDAR Study Group

Abstract

The objective was to analyze the effectiveness and safety of dual therapy with rilpivirine plus boosted-darunavir (RPV + bDRV) in real-life patients. Observational, retrospective, multi-center study in HIV+ patients who had received RPV + bDRV for 24 weeks to optimize/simplify their previous antiretroviral treatment. We determined the percentage of patients without virologic failure (2 consecutive viral loads > 50 copies/mL) at 24 weeks of treatment. The study included 161 patients from 15 hospitals with median age of 49 years; 29.3% had previous AIDS stage and median CD4+ lymphocyte nadir of 170 cells/uL. They had been diagnosed with HIV for a median of 17 years and had received 14 years of ART, with five previous treatment combinations, and 36.6% had a history of virological failure. The reasons for the switch were simplification/optimization (49.7%), toxicity/intolerance (17.4%), or inadequate effectiveness of previous ART (10.6%). Baseline VL of 50-1000 copies/mL was recorded in 25.5% of the patients. In the"intention-to-treat" analysis at 24 weeks, 87.6% of 161 patients continued the study treatment without virologic failure criteria. In the "on treatment" analysis (excluding patients who discontinued treatment with dual t...Continue Reading

Associated Clinical Trials

References

Nov 16, 2001·Revista Panamericana De Salud Pública = Pan American Journal of Public Health·UNKNOWN Panel on Clinical Practices for Treatment of HIV infection
Apr 8, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jose R ArribasUNKNOWN OK04 Study Group
Jul 3, 2009·Enfermedades infecciosas y microbiología clínica·Juan Pasquau Liaño
Feb 12, 2011·Antiviral Therapy·Federico PulidoChristiane Moecklinghoff
Dec 14, 2011·The Journal of Antimicrobial Chemotherapy·M A ValantinUNKNOWN MONOI ANRS 136 Study Group
Feb 2, 2012·Applied Health Economics and Health Policy·Juan PasquauChristiane Moecklinghoff
Feb 9, 2012·AIDS·Rebecca ScherzerMichael G Shlipak
Jun 15, 2012·AIDS·Marguerite GuiguetUNKNOWN FHDH-ANRS CO4
Aug 22, 2013·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Asa M MargolisAndrew Stolbach
Aug 28, 2013·The Journal of Clinical Investigation·S Alireza RabiRobert F Siliciano
Jan 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·Courtney V FletcherTimothy W Schacker
Aug 13, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ignacio Pérez-ValeroJosé R Arribas
Nov 15, 2014·Journal of the International AIDS Society·Jose ArribasMaria Blanca Hadacek
Nov 15, 2014·Journal of the International AIDS Society·Juan PasquauCarmen Hidalgo-Tenorio
Apr 25, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kathleen MulliganUNKNOWN Preexposure Prophylaxis Initiative Study Team
Oct 2, 2015·The Lancet. HIV·Nicholas I PatonUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Oct 11, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A Torres-CornejoA Gutiérrez-Valencia
Nov 26, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jan van LunzenPierre-Marie Girard

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.